Aktienanalyse zu Cencora Inc (COR)CORCencora Inc

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cencora Inc is a good buy right now due to its current price of $322.03, which is below the average analyst price target of $350, indicating potential upside. Additionally, the forward P/E ratio of 16.47 suggests the stock is reasonably valued compared to future earnings expectations. The recent increase in hedge fund buying by 2472.49% also signals strong institutional interest, which is a positive indicator for long-term investors. However, the main risk is the potential impact of changes in volume from its major client Walgreens, which could affect revenue streams.

15 analysts cover COR: 7 rate it Buy, 8 Hold and 0 Sell. The average price target is 415.38.